about
The risks of overlooking the diagnosis of secreting pituitary adenomasManaging Prolactinomas during PregnancyDrug-induced gynecomastia: an evidence-based reviewAdjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial.The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach.Management of macroprolactinomas.The risk for breast cancer is not evidently increased in women with hyperprolactinemia.Unusually high prolactin level for medication-induced hyperprolactinemia: a case report.HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.Anesthesia and Intensive care implications for pituitary surgery: Recent trends and advancements.Cognitive and perceptual disturbances in a young man.Managing prolactin-secreting adenomas during pregnancy.Clinical relevance of macroprolactin.Effect of dopaminergic drug treatment on surgical findings in prolactinomas.Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up.Imaging of pediatric pituitary endocrinopathiesTreatment of infertility in women with pituitary tumors.Endometrioid endometrial carcinoma indirectly caused by pituitary prolactinoma: a case report.Efficacy and safety of rapid escalation of cabergoline in comparison to conventional regimen for macroprolactinoma: A prospective, randomized trialFrom folklore to scientific evidence: breast-feeding and wet-nursing in islam and the case of non-puerperal lactation.Management of psychosis associated with a prolactinoma: case report and review of the literaturePituitary hyperplasia: a complication of the pseudomalabsorption of thyroxine.Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics.Pituitary disorders: an overview for the general physician.Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.Effect of bisphenol a on occurrence and progression of prolactinoma and its underlying mechanismsAdvances in the Diagnosis, Treatment, and Molecular Genetics of Pituitary Adenomas in Childhood.The birth and rise of a craniopharyngioma: the radiological evolution of an incidental craniopharyngioma detected on serial MRI during medical treatment of a macroprolactinoma.The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS).Cancer in Transgender People: Evidence and Methodological Considerations.The safety of treatments for prolactinomas.Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.Antipituitary antibodies in idiopathic hyperprolactinemic patients.Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients.Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma.Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
P2860
Q28076665-E06F4C7E-7DB3-42DE-8484-BDF41760AF33Q28080990-2AD5E443-F382-44A4-A2DB-B225E97DCEA5Q28272451-0228EF19-F6F5-4BEC-842E-78565DC524A8Q30490025-EC473684-6C86-49AD-9104-B41A308220C4Q33619940-2A5AF4E8-6102-44FD-8A40-0DD3BBD24535Q33721266-01EE0E90-F602-426D-AC81-0DF7EA245631Q33792371-B528F38E-A9F9-4376-B612-293538117C02Q34031912-9E3281BF-B9D4-424C-AB44-F25208F6310FQ34667106-C23C4564-0789-4ADF-A1FD-2424D14F8782Q34942996-5E9AD8AC-F90B-4EC7-9114-914B51956847Q35244587-F0B356CA-0DED-4D5B-BF13-F307EC13EBAAQ35846983-1FA85A4B-F7CB-4FF5-A961-860A87EDB842Q35951385-17D12DB7-0CB1-48D4-A55E-ED34FD0E9EC7Q36155952-F487BAEB-6FD9-4A3C-8A50-239C8CADEDB4Q36182003-E3353E95-575B-4554-96AE-25240793BEA4Q36266376-9D511DF7-1CE7-4519-9424-EE7EF0706681Q36331597-15FAF4C2-7402-4CB8-A803-42979C7AB456Q36605366-44096DF9-C7DC-4676-9CF9-B072A30947D7Q36613831-7AC72154-AE1A-4498-991A-D77C24867708Q36701123-CE93FE50-EE58-4D3E-9335-E4FA1D0F4231Q36735312-B3152712-525C-4210-A71D-79B205D88AA4Q36888242-0A4FCF1E-CEB2-4D1E-B728-50BF9260D4FCQ36916958-5E62979E-FB9D-42CA-84DA-4EA1C9A6E7E0Q37139774-5DDA1296-EB47-4FC7-A688-9180E7E085D7Q37150167-6221CE95-54C6-4B9B-A1C2-6CD0E624BC09Q37162791-7E5653F5-FF14-41C6-825B-5B6F61C90275Q37393412-7AF3BA56-86F6-425D-8373-FC1BB0FF0A91Q37425200-88A8593A-3B53-48EC-89B8-DF8E8DA23928Q37577813-D07A43AD-20A6-4876-A72B-6234AA7345A3Q38406655-C4BFA69F-3762-4EBA-8A1A-C57473A71760Q38685944-5C5513AF-DEE0-4C25-8010-C67692007A71Q38726058-4461F6F9-142F-4861-852E-F2431E72147EQ39198334-35649FCA-6DB6-4061-97E6-45A68DB0F960Q39317692-5B17B894-6B2A-4C66-821B-78D326E45ADBQ39504987-B604FC5E-B0FA-46A1-90FE-68EB9AD582BFQ40177113-36D35A2F-FA0D-42E5-A58F-0D8E491739B2Q44898008-8286C3DC-B636-4129-B43F-C2570993A842Q45158966-2F41EAF4-E65D-4249-98B1-FD38CE9E7F78Q45815395-950D014F-F734-4806-83F3-B2E359D279BAQ46190981-5EDF754A-BEA9-4689-BEA9-DB8B36852105
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinical practice. Prolactinoma.
@ast
Clinical practice. Prolactinoma.
@en
Clinical practice. Prolactinoma.
@nl
type
label
Clinical practice. Prolactinoma.
@ast
Clinical practice. Prolactinoma.
@en
Clinical practice. Prolactinoma.
@nl
prefLabel
Clinical practice. Prolactinoma.
@ast
Clinical practice. Prolactinoma.
@en
Clinical practice. Prolactinoma.
@nl
P356
P1476
Clinical practice. Prolactinoma.
@en
P304
P356
10.1056/NEJMCP025334
P407
P577
2003-11-01T00:00:00Z